Filing Flows › Longeveron (LGVN) › Q4 2025
Longeveron (LGVN) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 17, 2026
Longeveron (LGVN) reported revenue of $365K for the fourth quarter 2025 (Q4 2025), -39% from a year earlier and +166% from the quarter before.
Longeveron, Q4 2025: revenue $365K (-40% year over year), net loss $5.4M, operating cash flow −$5.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $365K | +166% | -39% |
| Operating profit | −$5.4M | — | — |
| Net earnings | −$5.4M | — | — |
| Operating cash flow | −$5.3M | — | — |
What changed
Revenue was $365K in Q4 2025, down 39% year over year and up 166% from the previous quarter. Clinical Trial Revenue was the largest line at 83% of revenue.
Gross margin was 70.4%, down 17.5 points from Q4 2024. Operating costs exceeded revenue by $5.4M, an operating margin of -1479.2%. Operating expenses grew 18% against a revenue fall of 39%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $5.4M, narrower than the previous quarter's $7.2M loss.
Operating cash flow was −$5.3M. Non-cash charges added back $278K of depreciation and amortization and $376K of share-based compensation. Working capital and other items used $506K.
Questions
What was Longeveron's revenue in the fourth quarter 2025?
Longeveron (LGVN) reported revenue of $365K for the fourth quarter 2025 (Q4 2025), -39% from a year earlier and +166% from the quarter before.
Source: Longeveron 10-K on SEC EDGAR.